

Jornadas Post-ACR en Reumatología

Coordinador: Dra. Mercedes Alperi López (Servicio de Reumatología, Hospital Universitario Central de Asturias).

ACTIVIDAD: curso teórico de actualización reumatológica.

DIRIGIDO A: el curso está dirigido a Residentes y adjuntos de Reumatología y otras especialidades de Asturias.

LOCALIZACIÓN: Aula de Reumatología, Consultas Externas, planta -1 B, Hospital Universitario Central de Asturias.

SECRETARIA TECNICA: PHOEMO

PROGRAMA PRELIMINAR

Día 12 de diciembre

15: 30 h: Presentación.

Dra. Mercedes Alperi López

Moderadores:

Dra. Mercedes Alperi López

Dr. Rubén Queiro Silva

15: 40 h. **Artritis Reumatoide asociada a enfermedad pulmonar intersticial: avances en screening, diagnóstico y fenotipo de paciente.**

Dra. Marta Loredó Martínez

16: 00 h. **Actualización de las guías ACR para el diagnóstico y tratamiento de la nefritis lúpica.**

Dr. Ignacio Braña Abascal

16: 20 h. **Manejo de FAMEs durante el embarazo.**

Dra. Stefanie Burger

16: 40 h. **Dermatomiositis juvenil Anti-MDA5: presentación clínica y tratamiento.**Dra. Estefanía Pardo Campo

17:00 h. Pausa-café

17:20 h. **Artritis Psoriásica. Selección de Abstracts**

Dr. Rubén Queiro Silva

- Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis
- Results from the Biopsy Driven Ebio Study: Enteseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis.
- Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies

17:40 h. **Artritis Reumatoide. Selección de Abstracts**

Dra. Mercedes Alperi López

- How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the "JAK-pot" Study).
- Baricitinib in Rheumatoid Arthritis - Interstitial Lung Disease. National Multicenter Study of 72 Patients.
- Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study.

18:00 h. **Espondiloartritis. Selección de Abstracts**

Dra. Sara Alonso Castro

- Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment.
- Ixekimumab or the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO.
- Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study.

18:20 h. Discusión

Todos los ponentes y moderadores

18:45: Conclusiones y cierre

Dra. Mercedes Alperi López

Día 6 de febrero

15: 30 h: Presentación

Dra. Mercedes Alperi López

Moderadores:

Dra. Mercedes Alperi López

Dr. Rubén Queiro Silva

15: 40 h. **Estratificación del riesgo en AR preclínica**

Dra. Mercedes Alperi López

16: 00 h. **¿Es la EMTC una entidad definida?**

Dr. Ignacio Braña Abascal

€16: 20 h. **Enfoque para la espondiloartritis difícil de tratar.**

Dra. Sara Alonso Castro

16:40 h. **Artritis Psoriásica. Selección de Abstracts**

Dr. Rubén Queiro Silva

- Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIONd Observational Cohort Study.
- Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials.
- Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis.

17:00 h. Pausa-café

17:20 h. **Embarazo. Selección de abstracts**

Dra. Stefanie Burger

- Results from the Certolizumab Pegol Pregnancy Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project.
- Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus.
- Glucocorticoids in Pregnancy and Lactation: Results of the Systematic Review Informing the EULAR Task Force on Antirheumatic Drugs in Reproduction, Pregnancy and Lactation.

17: 40 h. **Reumatología Pediátrica. Selección de abstracts.**

Dra. Estefanía Pardo Campo

- CD59 Complement Membrane Regulator Deficiency: 12 Years of Clinical and Molecular Follow-up of 29 Patients.
- Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children.
- Absolute Agreement and Inter-rater Reliability of a Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO) Amongst Radiologists.

18: 00 h. **Espondiloartritis. Selección de Abstracts**

Dr. Fernando Jirout Casillas

- The Assessment of SpondyloArthritis International Society (ASAS) Definition of Difficult-to-Manage Axial Spondyloarthritis.
- Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies.
- Characteristics of Axial Spondyloarthritis in Patients with Onset Chronic Low Back Pain After Age 45.

18:20 h. **Discusión.**

Todos los ponentes y moderadores

18:45: Conclusiones y cierre

Dra. Mercedes Alperi López

Día 13 de marzo

15: 30 h: Presentación

Dra. Mercedes Alperi López

Moderadores:

Dra. Mercedes Alperi López

Dr. Rubén Queiro Silva

15:40 h. Tratamiento de la Artritis Reumatoide en pacientes con comorbilidades complicadas: EPOC, enfermedad cardiovascular, enfermedad hepática y hepatitis vírica.

Dra. Marta Loredó Martínez

16:00 h. Controversias en el tratamiento de la vasculitis asociada a ANCA.

Dr. Ignacio Braña Abascal

16:20 h. Vasculitis pediátrica asociada a ANCA.

Dra. Estefanía Pardo Campo

16:40 h. Artritis Reumatoide. Selección de Abstracts.

Dra. Mercedes Alperi López

- Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial.
- Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial.
- Which Arthralgia Patients at Risk for RA Benefited from Treatment with Methotrexate? Results from the TREAT EARLIER Trial.

17:00 h. Pausa-café

17:20 h. Espondiloartritis/Artritis Psoriásica Selección de Abstracts.

Dra. Isabel Zapico

Dra. Sara Alonso Castro

- How Accurate Are Assessments by Local Radiologists of Sacroiliac Joint MRIs in Axial Spondyloarthritis and Psoriatic Arthritis in Routine Clinical Practice? Evidence from 873 Patients in Five European Countries.
- Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials.
- Sex- related Differences in Efficacy of Biologics in Axial Spondyloarthritis: A Systematic Review and Meta-analysis.
- Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study.
- Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class.
- Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain.

18:00 h. Discusión.

Todos los ponentes y moderadores

18:30 h. Conclusiones y cierre

Dra. Mercedes Alperi López



PHARMACEUTICAL COMPANIES
OF *Johnson & Johnson*



